Press Releases

Date Title  
Toggle Summary Quest Diagnostics to Provide Nationwide Access to Natera’s New Non-Invasive Prenatal Test
Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.
Toggle Summary Natera Launches Non-Invasive Prenatal Test Panorama™ with Best-in-Class Sensitivity, Specificity for Detection of Fetal Chromosomal Abnormalities
Panorama’s clinical validation data was presented live at the annual Society of Maternal Fetal Medicine Meeting on February 15, 2013. Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that the company’s non-invasive prenatal screening test, Panorama™, will
Toggle Summary Validation Data Presented by Natera Demonstrates Best-in-Class Specificity and Sensitivity of Non-Invasive Prenatal Test Panorama™
Data Presented at Society for Maternal-Fetal Medicine Annual Meeting Natera today announced the presentation of validation data demonstrating unmatched specificity and sensitivity of the company's non-invasive prenatal test, Panorama(TM). The presentation, titled "Use of targeted sequencing of SNPs

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.